ArticleEuropean journal of epidemiology2025
Association between aspirin use and the risk of incident nonalcoholic fatty liver disease.
Article in European journal of epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systemic metabolic dysfunction drives platelet-mediated inflammation, fibrogenesis, and hepatocarcinogenesis in metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Associations between use of aspirin and magnetic resonance imaging-derived liver fat and fibroinflammation.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the association between aspirin use and the incidence of nonalcoholic fatty liver disease (NAFLD). We included 53,490 participants from the Nurses' Health Study II, a prospective US cohort study. Cox proportional hazard regression analyses were performed to assess the association between time-updated aspirin use and the risk of incident NAFLD. The exposure data included the status, duration, frequency and dosage of aspirin use. Data on the use of nonaspirin nonsteroidal anti-inflammatory drugs and acetaminophen were also collected. Over 1.1 million person-years of follow-up and 3,640 cases of incident NAFLD were documented. Compared with nonusers, current aspirin users had a significantly greater risk of NAFLD (HR: 1.17, 95% CI: 1.05 - 1.29). The current use of nonsteroidal nonaspirin anti-inflammatory drugs was also positively associated with NAFLD risk (HR: 1.29, 95% CI: 1.11 - 1.50). There were no significant associations with the use of acetaminophen. Aspirin use was associated with a modestly increased risk of incident NAFLD. These findings need to be confirmed in future studies.
Indexed as
Identifiers
40184018What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.